20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ:PTGX) rusfertide clinical studies.
- The Company provided the requested individual patient clinical safety reports, updated the investigator brochure and patient informed consent forms.
- The clinical hold was initially triggered by a recent non-clinical finding in a 26-week rasH2 transgenic mouse model indicating benign and malignant subcutaneous skin tumors.
- The rasH2 signal also prompted a re-examination of the four cancer cases observed across all rusfertide clinical trials involving over 160 patients and a comprehensive review of the safety database.
- No additional cancer cases, and no other unexpected safety signals, surfaced in this process.
- Protagonist says it is actively preparing to initiate the phase 3 study for polycythemia vera in Q1 of 2022.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: PTGX shares are up 90.30% at $34.70 during the premarket session on Monday's last check.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!